Evidence map›Paper›PMID 38655375›Full record

ArticleIJTLD open2024

Isoniazid urine spectrophotometry for prediction of serum pharmacokinetics in adults with TB.

P S Rao, K Reed, N Modi, D Handler, K Petros de Guex, S Yu, L Kagan, R Reiss, N Narayanan, C A Peloquin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

P S RaoDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA.
K ReedSchool of Arts and Sciences, University of Virginia, Charlottesville, VA.
N ModiPublic Health Research Institute and Global Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, NJ.
D HandlerPublic Health Research Institute and Global Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, NJ.
K Petros de GuexDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA.
S YuDepartment of Pharmaceutics and Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers State University of New Jersey, Newark, NJ.
L KaganDepartment of Pharmaceutics and Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers State University of New Jersey, Newark, NJ.
R ReissPublic Health Research Institute and Global Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, NJ.
N NarayananDepartment of Pharmaceutics and Center of Excellence for Pharmaceutical Translational Research and Education, Ernest Mario School of Pharmacy, Rutgers State University of New Jersey, Newark, NJ.
C A PeloquinCollege of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
A LardizabalPublic Health Research Institute and Global Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, NJ.
C VinnardPublic Health Research Institute and Global Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, NJ.
T A ThomasDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA.
Y L XiePublic Health Research Institute and Global Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, NJ.
S K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA.

Funding

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3M
NIAID NIH HHS R01 AI137080
6 · The paper itself

Abstract

backgroundIsoniazid (INH) is an important drug in many TB regimens, and unfavorable treatment outcomes can be caused by suboptimal pharmacokinetics. Dose adjustment can be personalized by measuring peak serum concentrations; however, the process involves cold-chain preservation and laboratory techniques such as liquid chromatography (LC)/mass spectrometry (MS), which are unavailable in many high-burden settings. Urine spectrophotometry could provide a low-cost alternative with simple sampling and quantification methods.

methodsWe enrolled 56 adult patients on treatment for active TB. Serum was collected at 0, 1, 2, 4, 6, and 8 h for measurement of INH concentrations using validated LC-MS/MS methods. Urine was collected at 0-4, 4-8, and 8-24 h intervals, with INH concentrations measured using colorimetric methods.

resultsThe median peak serum concentration and total serum exposure over 24 h were 4.8 mg/L and 16.4 mg*hour/L, respectively. Area under the receiver operator characteristic curves for urine values predicting a subtherapeutic serum concentration (peak <3.0 mg/L) were as follows: 0-4 h interval (AUC 0.85, 95% CI 0.7-0.96), 0-8 h interval (AUC 0.85, 95% CI 0.71-0.96), and 0-24 h urine collection interval (AUC 0.84, 95% CI 0.68-0.96).

conclusionUrine spectrophotometry may improve feasibility of personalized dosing in high TB burden regions but requires further study of target attainment following dose adjustment based on a urine threshold.

Indexed as

INHLC-MS/MSPKtuberculosis

Identifiers

PMID38655375
PMCPMC11037464

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.